Announcement
02 Feb 2021
In February 2020, Canadian Government provided funding to Edesa Biotech to support the efforts on the development of monoclonal antibody therapy for acute respiratory distress syndrome, which is the leading cause of COVID-19 deaths.
Source
Sign in to access
Number of interventions
1
1 certainly harmful
0 likely harmful
0 liberalising
List of interventions
Implementation date
02 Feb 2021
Revocation date:
No revocation date
Updated: 02 Feb 2021
State loan
In force
On February 2, 2021, Edesa Biotech announced securing CAD 14 million (USD 11 million) from the Canadian government to complete the Phase 2 clinical studies of its investigational drug EB05 for the ...
Sign in to see more
Related State Acts
12 Oct 2023
Canada: Government announces CAD 23 million in state aid to Edesa Biotech
18 May 2021
Canada: Government announces funding for a Canadian biomanufacturing company
02 Feb 2021
Canada: Government provides funding for the production of ribonucleic acid vaccines and future genetic medicines in Canada
23 Mar 2020
Canada: Government allocates CAD 792 million for the development and production of medical countermeasures to COVID-19
Threads
See all
This state act is not part of any Thread yet.